Literature DB >> 25168936

Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.

Jerrold H Levy1.   

Abstract

New oral anticoagulants (NOACs) are increasingly replacing vitamin K antagonists and older parenteral agents in clinical practice. NOACs offer several advantages compared with standard agents, including rapid onset of action, fixed dosing, and no requirement for routine coagulation monitoring. However, like all anticoagulants, NOACs carry a risk of bleeding. Here, we discuss the pharmacology and safety of NOACs, with particular emphasis on the risks of bleeding associated with NOACs versus standard anticoagulants, and we provide an overview of current bleeding management strategies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apixaban; Bleeding; Dabigatran; Prothrombin complex concentrates; Rivaroxaban; Safety

Mesh:

Substances:

Year:  2014        PMID: 25168936     DOI: 10.1016/j.cll.2014.06.003

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  1 in total

Review 1.  Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Tingting Wu; Chenyang Lv; Lishui Wu; Wenjun Chen; Meina Lv; Shaojun Jiang; Jinhua Zhang
Journal:  J Neurol       Date:  2021-02-17       Impact factor: 6.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.